Review
Clinical Significance of Vitamin D Deficiency in Primary Hyperparathyroidism, and Safety of Vitamin D Therapy
Abstract
Vitamin D deficiency occurs more frequently in patients with primary hyperparathyroidism (PHPT) compared with the general population, and is usually associated with an aggravated form of the disease. Current guidelines recommend measurement of serum levels of 25-hydroxy vitamin D (25-OHD) in all patients with PHPT, and their repletion if the levels are less than 50 mmol/L (20 ng/mL). Limited data suggest that vitamin D treatment is generally safe in subjects with mild PHPT and coexisting vitamin D deficiency. Adverse effects include hypercalcuria and, less commonly, exacerbation of hypercalcemia. Well-designed trials are needed to evaluate the safety of vitamin D replacement therapy in a wide spectrum of patients with concomitant PHPT and vitamin D deficiency. These trials should address the impact of such therapy on the complications and course of PHPT.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340–350.
2. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insuffiency. Lancet 1998;351:805–806.
3. Woodhouse NJ, Doyle FH, Joplin GF. Vitamin-D deficiency and primary hyperparathyroidism. Lancet 1971;2:283–286.
4. Lumb GA, Stanbury SW. Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am J Med 1974;56:833–839.
5. Moosgaard B, Vestergaard P, Heickendorff L, et al. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63:506–513.
6. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation Clinical Trial. J Clin Endocrinol Metab 2001;86:1212–1221.
7. Boudou P, Ibrahim F, Cormier C, et al. A very high incidence of low 25 hydroxyvitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest 2006;29:511–515.
8. Silverberg SJ, Shane E, Dempster DW, et al. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med 1999;107:561–567.
9. Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sistamibi scan. Arch Otolaryngol Head Neck Surg 2008;134:1071–1075.
10. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med 2009;169:626–632.
11. Clements MR, Davies M, Hayes ME, et al. The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 1992;37:17–27.
12. Davies M, Heys SE, Selby PL, et al. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxy vitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab 1997;82:209–212.
13. Bolland MJ, Grey AB, Gamble GD, et al. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005;90:1525–1530.
14. Arunabh S, Pollack S, Yeh J, et al. Body fat content and 25-hydroxyvitamin D levels in healthy men. J Clin Endocrinol Metab 2003;88:157–161.
15. Kantorovich V, Gacad MA, Seeger LL, et al. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab 2000;85:3541–3543.
16. Rao DS, Honasoge M, Divine GW, et al. Effect of vitamin D nutrition on parathyroid adenoma weight: Pathogenetic and clinical implications. J Clin Endocrinol Metab 2000;85:1054–1058.
17. Beyer TD, Chen EL, Nilubol N, et al. Short-term outcomes of parathyroidectomy in patients with or without 25-hydroxy vitamin D insufficiency. J Surg Res 2007;143:145–150.
18. Untch BR, Barfield ME, Dar M, et al. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007;142:1022–1026.
19. Stewart ZA, Blackford A, Somervell H, et al. 25-hydroxyvitamin D deficiency is a risk factor for symptoms for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005;138:1018–1025.
20. Moosgaard B, Christensen SE, Vestergaard P, et al. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf) 2008;68:707–715.
21. Carnevale V, Manfredi G, Romagnoli E, et al. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal change? Clin Endocrinol (Oxf) 2004;60:81–86.
22. Nordenström E, Westerdahl J, Lindergård B, et al. Multifactorial risk for bone fractures in primary hyperparathyroidism. World J Surg 2002;26:1463–1467.
23. Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001–3005.
24. Grey A, Lucas J, Horne A, et al. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005;90:2122–2126.
25. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol 2009;161:189–193.
26. Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009;36:305–310.
27. Grubbs EG, Rafeeq S, Jimenez C, et al. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008;144:852–858.
28. Carter GD, Berry JL, Gunter E, et al. Proficiency testing of 25-hydroxyvitamin D (25-OHD) assays. J Steroid Biochem Mol Biol 2010;121:176–179.
